NKGen Biotech, Inc. Common Stock (NKGN) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

NKGen Biotech, Inc. Common Stock

NKGN

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

17M

Biotechnology

0.48USD

-0.01 ( -2.80%)

Relative Strenght

90

Volume Buzz

-92%

Earning Acce

No

Dist 52w H.

88%

Quote Panel

Updated January 13, 2025

1W -15.13 % 1M 5.04 % 3M 93.13 % 1Y -82.46 %

Key Metrics

Market Cap
16.88M
Shares Outstanding
35.52M
Share in Float
18.56M
Dividende
0

Earning Date
No Data
Price Target
0.4753
Average Volume
1.44M
Beta
0.524

Range
0.203-4.06
Industry
Biotechnology
Website
https://www.grafacq.com
Sector
Healthcare

Fundamentals

Relative Strength

NKGN

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

No Data Available

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Earnings Growth

YoY

Current

Estimates

Q2.22

+209%

0.22
vs -0.20

Q3.22

-81%

0.04
vs 0.22

Q4.22

N/A

-0.14
vs -0.06

Q1.23

-81%

0.02
vs 0.09

Q2.23

N/A

-2.48
vs 0.22

Q3.23

N/A

-2.48
vs 0.04

Q4.23

N/A

-1.54
vs -0.14

Q1.24

N/A

-1.68
vs 0.02

Q2.24

N/A

-0.67
vs -2.48

Q3.24

+162%

1.54
vs -2.48

Sales Growth

YoY

Current

Estimates

Q1.22

NA

NA vs NA

Q2.22

NA

NA vs NA

Q3.22

NA

3K vs NA

Q4.22

NA

NA vs NA

Q1.23

NA

NA vs NA

Q2.23

NA

NA vs NA

Q3.23

-100%

NA vs 3K

Q4.23

NA

NA vs NA

Q1.24

NA

NA vs NA

Q2.24

NA

NA vs NA

Return on Equity

QoQ

Q3.22

+1%

0.01
vs 0.03

Q4.22

-2%

-0.02
vs 0.01

Q1.23

+0%

0
vs -0.02

Q2.23

-3%

-0.03
vs 0

Q3.23

+82%

0.82
vs -0.03

Q4.23

+83%

0.83
vs 0.82

Q1.24

+12%

0.12
vs 0.83

Q2.24

+23%

0.23
vs 0.12

Institutionnal Ownership

Earnings Growth

Latest News

NKGN

globenewswire.com

8 hours ago

NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

NKGN

globenewswire.com

8 hours ago

NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)

NKGN

globenewswire.com

8 hours ago

NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

NKGN

globenewswire.com

8 hours ago

NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial

NKGN

globenewswire.com

16 hours ago

NKGen Biotech Selected as Stalking Horse Bidder for NKMax

NKGN

globenewswire.com

16 hours ago

NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel

New Feature Coming Soon, Stay Tuned!

Shape

Shape